Strong cash position to fund aldoxorubicin clinical trials including Phase 2 trials in glioblastoma and Kaposi's sarcoma in 2013, and a Global Phase 3 pivotal trial for soft tissue sarcoma in the first quarter of 2014 )-- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today reported financial ... (more)
http://eon.businesswire.com/news/eon/20131029005313/en/CytRx-Reports-2013-Quarter-Financial-Results
http://eon.businesswire.com/news/eon/20131029005313/en/CytRx-Reports-2013-Quarter-Financial-Results
No comments:
Post a Comment